RT Journal Article
SR Electronic
T1 Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1592
OP 1600
DO 10.1136/annrheumdis-2019-215933
VO 78
IS 11
A1 David Bursill
A1 William J Taylor
A1 Robert Terkeltaub
A1 Abhishek Abhishek
A1 Alexander K So
A1 Ana Beatriz Vargas-Santos
A1 Angelo Lino Gaffo
A1 Ann Rosenthal
A1 Anne-Kathrin Tausche
A1 Anthony Reginato
A1 Bernhard Manger
A1 Carlo Sciré
A1 Carlos Pineda
A1 Caroline van Durme
A1 Ching-Tsai Lin
A1 Congcong Yin
A1 Daniel Arthur Albert
A1 Edyta Biernat-Kaluza
A1 Edward Roddy
A1 Eliseo Pascual
A1 Fabio Becce
A1 Fernando Perez-Ruiz
A1 Francisca Sivera
A1 Frédéric Lioté
A1 Georg Schett
A1 George Nuki
A1 Georgios Filippou
A1 Geraldine McCarthy
A1 Geraldo da Rocha Castelar Pinheiro
A1 Hang-Korng Ea
A1 Helena De Almeida Tupinambá
A1 Hisashi Yamanaka
A1 Hyon K Choi
A1 James Mackay
A1 James R ODell
A1 Janitzia Vázquez Mellado
A1 Jasvinder A Singh
A1 John D Fitzgerald
A1 Lennart T H Jacobsson
A1 Leo Joosten
A1 Leslie R Harrold
A1 Lisa Stamp
A1 Mariano Andrés
A1 Marwin Gutierrez
A1 Masanari Kuwabara
A1 Mats Dehlin
A1 Matthijs Janssen
A1 Michael Doherty
A1 Michael S Hershfield
A1 Michael Pillinger
A1 N Lawrence Edwards
A1 Naomi Schlesinger
A1 Nitin Kumar
A1 Ole Slot
A1 Sebastien Ottaviani
A1 Pascal Richette
A1 Paul A MacMullan
A1 Peter T Chapman
A1 Peter E Lipsky
A1 Philip Robinson
A1 Puja P Khanna
A1 Rada N Gancheva
A1 Rebecca Grainger
A1 Richard J Johnson
A1 Ritch Te Kampe
A1 Robert T Keenan
A1 Sara K Tedeschi
A1 Seoyoung Kim
A1 Sung Jae Choi
A1 Theodore R Fields
A1 Thomas Bardin
A1 Till Uhlig
A1 Tim Jansen
A1 Tony Merriman
A1 Tristan Pascart
A1 Tuhina Neogi
A1 Viola Klück
A1 Worawit Louthrenoo
A1 Nicola Dalbeth
YR 2019
UL http://ard.bmj.com/content/78/11/1592.abstract
AB Objective There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout.Methods A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease state labels and definitions.Results The content analysis identified 13 unique disease states and a total of 63 unique labels. The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established consensus agreement for eight disease state labels and definitions. The agreed labels were as follows: ‘asymptomatic hyperuricaemia’, ‘asymptomatic monosodium urate crystal deposition’, ‘asymptomatic hyperuricaemia with monosodium urate crystal deposition’, ‘gout’, ‘tophaceous gout’, ‘erosive gout’, ‘first gout flare’ and ‘recurrent gout flares’. There was consensus agreement that the label ‘gout’ should be restricted to current or prior clinically evident disease caused by monosodium urate crystal deposition (gout flare, chronic gouty arthritis or subcutaneous tophus).Conclusion Consensus agreement has been established for the labels and definitions of eight gout disease states, including ‘gout’ itself. The Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.